AB
Business activity cleared — no excluded categories detected
Source: stored filing inputs · Balance sheet as of 2026-06-30 · Income statement as of 2025-12-31
Arbutus Biopharma Corporation (ABUS) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification, same as the Discord bot's !halal command.
Business activity: cleared (no excluded categories detected)
Source: stored filing inputs · Balance sheet as of 2026-06-30 · Income statement as of 2025-12-31
Combined verdict: AAOIFI Non Compliant Usmani Non Compliant Dow Jones Islamic Non Compliant S&P Shariah Non Compliant MSCI Islamic Non Compliant MSCI Islamic M Non Compliant FTSE Shariah Non Compliant
ℹ️ AAOIFI, Usmani, Dow Jones Islamic, S&P Shariah, MSCI Islamic, MSCI Islamic M, FTSE Shariah screen this company as Non-Compliant on the financial ratios alone — a ratio failure is decisive on its own, so those verdicts stand regardless of what the business-activity screen concluded.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 59.90 | NEUTRAL |
| Stochastic %K (14) | 28.26 | NEUTRAL |
| CCI (20) | 38.74 | NEUTRAL |
| Williams %R (14) | -71.74 | NEUTRAL |
| MACD (12,26,9) | -0.01 | SELL |
| ROC (10) | -1.35 | SELL |
| Momentum (10) | -0.07 | SELL |
| EMA (10) | 5.11 | BUY |
| SMA (10) | 5.12 | SELL |
| EMA (20) | 5.02 | BUY |
| SMA (20) | 5.03 | BUY |
| EMA (30) | 4.93 | BUY |
| SMA (30) | 4.86 | BUY |
| EMA (50) | 4.82 | BUY |
| SMA (50) | 4.78 | BUY |
| EMA (100) | 4.67 | BUY |
| SMA (100) | 4.58 | BUY |
| EMA (200) | 4.57 | BUY |
| SMA (200) | 4.50 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Background via Yahoo Finance — informational, not part of the verdict.
No real edge — avoid
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 43 |
| ⏰ 4H | RANGING | 40 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
